Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with …
M Stevenson, R Archer, J Tosh… - Health Technology …, 2016 - eprints.whiterose.ac.uk
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with
increasing disability, reduced quality of life and substantial costs (as a result of both …
increasing disability, reduced quality of life and substantial costs (as a result of both …
Osteoimmunology: major and costimulatory pathway expression associated with chronic inflammatory induced bone loss
The field of osteoimmunology has emerged in response to the range of evidences
demonstrating the close interrelationship between the immune system and bone …
demonstrating the close interrelationship between the immune system and bone …
[HTML][HTML] Rheumatoid Arthritis: Early diagnosis and treatment outcomes
B Heidari - Caspian journal of internal medicine, 2011 - ncbi.nlm.nih.gov
Rheumatoid arthritis (RA) is an inflammatory progressive disease which in the absence of
appropriate treatment can lead to joint destruction and disability. Prognosis of RA may be …
appropriate treatment can lead to joint destruction and disability. Prognosis of RA may be …
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for …
J Detert, H Bastian, J Listing, A Weiß… - Annals of the …, 2013 - ard.bmj.com
Objective To investigate the long-term effects of induction therapy with adalimumab (ADA)
plus methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naïve …
plus methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naïve …
Cost-effectiveness of biosimilars vs leflunomide in patients with rheumatoid arthritis
K Peng, SCW Chan, Y Wang, FWT Cheng… - JAMA Network …, 2024 - jamanetwork.com
Importance Among patients with rheumatoid arthritis (RA) who had an inadequate response
to methotrexate, a treatment sequence initiated with biosimilar disease-modifying …
to methotrexate, a treatment sequence initiated with biosimilar disease-modifying …
[HTML][HTML] Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics …
Background Personalized medicine technologies can improve individual health by
delivering the right dose of the right drug to the right patient at the right time but create …
delivering the right dose of the right drug to the right patient at the right time but create …
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of …
M Schoels, J Wong, DL Scott, A Zink… - Annals of the …, 2010 - ard.bmj.com
Objective To review the cost effectiveness of rheumatoid arthritis (RA) treatments and inform
the clinical recommendations by the European League Against Rheumatism. Methods A …
the clinical recommendations by the European League Against Rheumatism. Methods A …
The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review
JT Joensuu, S Huoponen, KJ Aaltonen, YT Konttinen… - PloS one, 2015 - journals.plos.org
Background and Objectives Economic evaluations provide information to aid the optimal
utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) …
utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) …
How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?—MTX in the treat-to-target strategy
PC Taylor, A Balsa Criado, AB Mongey… - Journal of clinical …, 2019 - mdpi.com
Methotrexate (MTX) is a remarkable drug with a key role in the management of rheumatoid
arthritis (RA) at every stage of its evolution. Its attributes include good overall efficacy for …
arthritis (RA) at every stage of its evolution. Its attributes include good overall efficacy for …
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
Crohn's disease is a chronic inflammatory disorder that follows a progressive and
destructive course. Ultimately, uncontrolled inflammation leads to bowel damage from …
destructive course. Ultimately, uncontrolled inflammation leads to bowel damage from …